#### Diseases /

#### B-Cell Non-Hodgkin Lymphoma

##### Back to Diseases List

###### Associated Genetic Biomarkers

#### Overview

**NCI Definition:** The most common type of non-Hodgkin lymphoma. It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003 [1]

B-cell non-hodgkin lymphomas most frequently harbor alterations in KMT2D, TNFAIP3, CREBBP, TP53, and SOCS1 [2].

KMT2D Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Mutation are the most common alterations in B-cell non-hodgkin lymphoma [2].

#### Clinical Trials

There are 40 clinical trials for B-cell non-hodgkin lymphoma, of which 36 are open and 4 are completed or closed. Of the trials that contain B-cell non-hodgkin lymphoma as an inclusion criterion, 15 are phase 1 (13 open), 14 are phase 1/phase 2 (13 open), 7 are phase 2 (7 open), 3 are phase 3 (2 open), and 1 is no phase specified (1 open).

MYC, BCL2, and BCL6 are the most frequent gene inclusion criteria for B-cell non-hodgkin lymphoma clinical trials [3].

Cyclophosphamide, fludarabine, and nivolumab are the most common interventions in B-cell non-hodgkin lymphoma clinical trials.

#### Significant Genes in B-Cell Non-Hodgkin Lymphoma

ABL1 +

ABL1 is mutated in 1.33% of B-cell non-hodgkin lymphoma patients [2].

ABL1 is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ABL1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and vemurafenib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with ABL1 mutations as inclusion criteria [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain AFF1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with AFF1 mutations as inclusion criteria [3].

AKT1 +

AKT1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with AKT1 mutations as inclusion criteria [3].

AKT2 +

AKT2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with AKT2 mutations as inclusion criteria [3].

AKT3 +

AKT3 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with AKT3 mutations as inclusion criteria [3].

ALK +

ALK is mutated in 1.35% of B-cell non-hodgkin lymphoma patients [2].

ALK is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

Nivolumab, autologous hematopoietic stem cell transplatation, and vemurafenib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with ALK mutations as inclusion criteria [3].

ATM +

ATM is mutated in 1.33% of B-cell non-hodgkin lymphoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with ATM mutations as inclusion criteria [3].

ATR +

ATR is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with ATR mutations as inclusion criteria [3].

BARD1 +

BARD1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with BARD1 mutations as inclusion criteria [3].

BCL2 +

BCL2 is mutated in 9.59% of B-cell non-hodgkin lymphoma patients [2].

BCL2 is an inclusion eligibility criterion in 7 clinical trials for B-cell non-hodgkin lymphoma, of which 7 are open and 0 are closed. Of the trials that contain BCL2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

Fludarabine, nivolumab, and 6,8-bis(benzylthio)octanoic acid are the most frequent therapies in B-cell non-hodgkin lymphoma trials with BCL2 mutations as inclusion criteria [3].

BCL6 +

BCL6 is an inclusion eligibility criterion in 7 clinical trials for B-cell non-hodgkin lymphoma, of which 7 are open and 0 are closed. Of the trials that contain BCL6 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

Fludarabine, nivolumab, and 6,8-bis(benzylthio)octanoic acid are the most frequent therapies in B-cell non-hodgkin lymphoma trials with BCL6 mutations as inclusion criteria [3].

BCR +

BCR is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain BCR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and vemurafenib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with BCR mutations as inclusion criteria [3].

BRAF +

BRAF is mutated in 2.67% of B-cell non-hodgkin lymphoma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with BRAF mutations as inclusion criteria [3].

BRCA1 +

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with BRCA1 mutations as inclusion criteria [3].

BRCA2 +

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with BRCA2 mutations as inclusion criteria [3].

BRIP1 +

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with BRIP1 mutations as inclusion criteria [3].

CBFB +

CBFB is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CBFB status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Bet inhibitor ft-1101 and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with CBFB mutations as inclusion criteria [3].

CCND1 +

CCND1 is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

CCND1 is an inclusion eligibility criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with CCND1 mutations as inclusion criteria [3].

CDK4 +

CDK4 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with CDK4 mutations as inclusion criteria [3].

CDK6 +

CDK6 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with CDK6 mutations as inclusion criteria [3].

CDKN2A +

CDKN2A is mutated in 5.41% of B-cell non-hodgkin lymphoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with CDKN2A mutations as inclusion criteria [3].

CHEK1 +

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with CHEK1 mutations as inclusion criteria [3].

CHEK2 +

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with CHEK2 mutations as inclusion criteria [3].

CSF1R +

CSF1R is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with CSF1R mutations as inclusion criteria [3].

DEK +

DEK is an inclusion eligibility criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain DEK status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with DEK mutations as inclusion criteria [3].

EGFR +

EGFR is mutated in 2.67% of B-cell non-hodgkin lymphoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with EGFR mutations as inclusion criteria [3].

ELL +

ELL is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ELL status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with ELL mutations as inclusion criteria [3].

ERBB2 +

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with ERBB2 mutations as inclusion criteria [3].

EZH2 +

EZH2 is mutated in 6.76% of B-cell non-hodgkin lymphoma patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Prednisolone and tazemetostat are the most frequent therapies in B-cell non-hodgkin lymphoma trials with EZH2 mutations as inclusion criteria [3].

FANCA +

FANCA is mutated in 2.74% of B-cell non-hodgkin lymphoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCA mutations as inclusion criteria [3].

FANCB +

FANCB is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCB mutations as inclusion criteria [3].

FANCC +

FANCC is mutated in 2.74% of B-cell non-hodgkin lymphoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCC mutations as inclusion criteria [3].

FANCD2 +

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCD2 mutations as inclusion criteria [3].

FANCE +

FANCE is mutated in 1.82% of B-cell non-hodgkin lymphoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCE mutations as inclusion criteria [3].

FANCF +

FANCF is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCF mutations as inclusion criteria [3].

FANCG +

FANCG is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCG mutations as inclusion criteria [3].

FANCI +

FANCI is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCI mutations as inclusion criteria [3].

FANCL +

FANCL is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCL mutations as inclusion criteria [3].

FANCM +

FANCM is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FANCM mutations as inclusion criteria [3].

FBXW7 +

FBXW7 is mutated in 1.33% of B-cell non-hodgkin lymphoma patients [2].

FBXW7 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FBXW7 mutations as inclusion criteria [3].

FGFR1 +

FGFR1 is mutated in 1.35% of B-cell non-hodgkin lymphoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FGFR1 mutations as inclusion criteria [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FGFR2 mutations as inclusion criteria [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FGFR3 mutations as inclusion criteria [3].

FLCN +

FLCN is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLCN status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FLCN mutations as inclusion criteria [3].

FLT1 +

FLT1 is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FLT1 mutations as inclusion criteria [3].

FLT3 +

FLT3 is mutated in 1.33% of B-cell non-hodgkin lymphoma patients [2].

FLT3 is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain FLT3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and vemurafenib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FLT3 mutations as inclusion criteria [3].

FLT4 +

FLT4 is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with FLT4 mutations as inclusion criteria [3].

IGH +

IGH is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IRF4 +

IRF4 is mutated in 11.11% of B-cell non-hodgkin lymphoma patients [2].

IRF4 is an inclusion eligibility criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

Autologous icasp9-cd19-expressing t-lymphocytes, bendamustine, and fludarabine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with IRF4 mutations as inclusion criteria [3].

KDR +

KDR is mutated in 1.33% of B-cell non-hodgkin lymphoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with KDR mutations as inclusion criteria [3].

KIT +

KIT is mutated in 1.33% of B-cell non-hodgkin lymphoma patients [2].

KIT is an inclusion eligibility criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

Bet inhibitor ft-1101, axitinib, and vemurafenib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with KIT mutations as inclusion criteria [3].

KMT2A +

KMT2A is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

KMT2A is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain KMT2A status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with KMT2A mutations as inclusion criteria [3].

MCPH1 +

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MCPH1 mutations as inclusion criteria [3].

MECOM +

MECOM is mutated in 1.82% of B-cell non-hodgkin lymphoma patients [2].

MECOM is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain MECOM status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [3].

Bet inhibitor ft-1101, cdk9 inhibitor azd4573, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MECOM mutations as inclusion criteria [3].

MET +

MET is mutated in 2.67% of B-cell non-hodgkin lymphoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MET mutations as inclusion criteria [3].

MLF1 +

MLF1 is an inclusion eligibility criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MLF1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

Bet inhibitor ft-1101, cdk9 inhibitor azd4573, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MLF1 mutations as inclusion criteria [3].

MLH1 +

MLH1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Anti-pd-l1 monoclonal antibody ck-301 is the most frequent therapy in B-cell non-hodgkin lymphoma trials with MLH1 mutations as inclusion criteria [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain MLLT1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MLLT1 mutations as inclusion criteria [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain MLLT10 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MLLT10 mutations as inclusion criteria [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain MLLT3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MLLT3 mutations as inclusion criteria [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain MLLT4 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MLLT4 mutations as inclusion criteria [3].

MRE11A +

MRE11A is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MRE11A mutations as inclusion criteria [3].

MSH2 +

MSH2 is mutated in 2.74% of B-cell non-hodgkin lymphoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Anti-pd-l1 monoclonal antibody ck-301 is the most frequent therapy in B-cell non-hodgkin lymphoma trials with MSH2 mutations as inclusion criteria [3].

MSH6 +

MSH6 is mutated in 2.74% of B-cell non-hodgkin lymphoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Anti-pd-l1 monoclonal antibody ck-301 is the most frequent therapy in B-cell non-hodgkin lymphoma trials with MSH6 mutations as inclusion criteria [3].

MTOR +

MTOR is mutated in 4.11% of B-cell non-hodgkin lymphoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MTOR mutations as inclusion criteria [3].

MYC +

MYC is mutated in 5.48% of B-cell non-hodgkin lymphoma patients [2].

MYC is an inclusion eligibility criterion in 9 clinical trials for B-cell non-hodgkin lymphoma, of which 9 are open and 0 are closed. Of the trials that contain MYC status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 4 are phase 1/phase 2 (4 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

Cyclophosphamide, etoposide, and rituximab are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MYC mutations as inclusion criteria [3].

MYH11 +

MYH11 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYH11 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Bet inhibitor ft-1101 and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with MYH11 mutations as inclusion criteria [3].

NBN +

NBN is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with NBN mutations as inclusion criteria [3].

NF1 +

NF1 is mutated in 2.74% of B-cell non-hodgkin lymphoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with NF1 mutations as inclusion criteria [3].

NF2 +

NF2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with NF2 mutations as inclusion criteria [3].

NPM1 +

NPM1 is an inclusion eligibility criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

Bet inhibitor ft-1101, cdk9 inhibitor azd4573, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with NPM1 mutations as inclusion criteria [3].

NTRK3 +

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with NTRK3 mutations as inclusion criteria [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain NUP214 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with NUP214 mutations as inclusion criteria [3].

PALB2 +

PALB2 is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PALB2 mutations as inclusion criteria [3].

PBX1 +

PBX1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Cyclosporine, filgrastim, and mycophenolate mofetil are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PBX1 mutations as inclusion criteria [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PDGFRA mutations as inclusion criteria [3].

PDGFRB +

PDGFRB is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PDGFRB mutations as inclusion criteria [3].

PIK3CA +

PIK3CA is mutated in 2.67% of B-cell non-hodgkin lymphoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PIK3CA mutations as inclusion criteria [3].

PIK3R1 +

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PIK3R1 mutations as inclusion criteria [3].

PMS2 +

PMS2 is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Anti-pd-l1 monoclonal antibody ck-301 is the most frequent therapy in B-cell non-hodgkin lymphoma trials with PMS2 mutations as inclusion criteria [3].

POLD1 +

POLD1 is mutated in 2.7% of B-cell non-hodgkin lymphoma patients [2].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with POLD1 mutations as inclusion criteria [3].

POLE +

POLE is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with POLE mutations as inclusion criteria [3].

PTCH1 +

PTCH1 is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PTCH1 mutations as inclusion criteria [3].

PTEN +

PTEN is mutated in 6.67% of B-cell non-hodgkin lymphoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PTEN mutations as inclusion criteria [3].

RAD50 +

RAD50 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RAD50 mutations as inclusion criteria [3].

RAD51 +

RAD51 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RAD51 mutations as inclusion criteria [3].

RAD51B +

RAD51B is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RAD51B mutations as inclusion criteria [3].

RAD51C +

RAD51C is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RAD51C mutations as inclusion criteria [3].

RAD51D +

RAD51D is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RAD51D mutations as inclusion criteria [3].

RET +

RET is mutated in 2.67% of B-cell non-hodgkin lymphoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RET mutations as inclusion criteria [3].

RHEB +

RHEB is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RHEB status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RHEB mutations as inclusion criteria [3].

ROS1 +

ROS1 is mutated in 2.74% of B-cell non-hodgkin lymphoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with ROS1 mutations as inclusion criteria [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain RPN1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [3].

Bet inhibitor ft-1101, cdk9 inhibitor azd4573, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RPN1 mutations as inclusion criteria [3].

RUNX1 +

RUNX1 is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Bet inhibitor ft-1101 and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RUNX1 mutations as inclusion criteria [3].

RUNX1T1 +

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1T1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Bet inhibitor ft-1101 and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with RUNX1T1 mutations as inclusion criteria [3].

SLX4 +

SLX4 is mutated in 12.0% of B-cell non-hodgkin lymphoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with SLX4 mutations as inclusion criteria [3].

SMO +

SMO is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with SMO mutations as inclusion criteria [3].

SRC +

SRC is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with SRC mutations as inclusion criteria [3].

STK11 +

STK11 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with STK11 mutations as inclusion criteria [3].

TCF3 +

TCF3 is mutated in 1.37% of B-cell non-hodgkin lymphoma patients [2].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Cyclosporine, filgrastim, and mycophenolate mofetil are the most frequent therapies in B-cell non-hodgkin lymphoma trials with TCF3 mutations as inclusion criteria [3].

TP53 +

TP53 is mutated in 14.67% of B-cell non-hodgkin lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

Bet inhibitor ft-1101, allogeneic hematopoietic stem cell transplantation, and azacitidine are the most frequent therapies in B-cell non-hodgkin lymphoma trials with TP53 mutations as inclusion criteria [3].

TSC1 +

TSC1 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with TSC1 mutations as inclusion criteria [3].

TSC2 +

TSC2 is mutated in 5.48% of B-cell non-hodgkin lymphoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with TSC2 mutations as inclusion criteria [3].

VHL +

VHL is mutated in 1.33% of B-cell non-hodgkin lymphoma patients [2].

VHL is an inclusion eligibility criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with VHL mutations as inclusion criteria [3].

#### Disease Details

#### References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. *Cancer Discovery*. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.